[1]徐永康,付舒敏,李　丹,等.肝动脉灌注化疗联合系统治疗在原发性肝癌中的研究进展[J].介入放射学杂志,2023,32(01):94-97.
　XU Yongkang,FU Shumin,LI Dan,et al.Research progress in hepatic arterial infusion chemotherapy combined with systemic therapy for the treatment of primary hepatocellular carcinoma[J].journal interventional radiology,2023,32(01):94-97.
点击复制

肝动脉灌注化疗联合系统治疗在原发性肝癌中的研究进展()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年01
页码:
94-97
栏目:
综述
出版日期:
2023-02-13

文章信息/Info

Title:
Research progress in hepatic arterial infusion chemotherapy combined with systemic therapy for the treatment of primary hepatocellular carcinoma
作者:
徐永康; 　付舒敏; 　李　丹; 　毛　野; 　吴建兵
Author(s):
XU Yongkang;  FU Shumin;  LI Dan;  MAO Ye;  WU Jianbing.
Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province 330006, China
关键词:
【关键词】原发性肝癌; 肝动脉灌注化疗; 分子靶向治疗; 免疫治疗
文献标志码:
A
摘要:
【摘要】　原发性肝癌是常见的恶性肿瘤之一，肝动脉灌注化疗（HAIC）和系统治疗是中晚期肝癌主要的治疗方式。HAIC通过方案及介入技术的改进，能够有效控制肝内病灶且安全性好。系统治疗从单一的靶向药物或免疫治疗进入靶免联合的时代，治疗手段日益丰富。但无论是HAIC或系统治疗，单一治疗效果有限。近年来，HAIC联合系统治疗能有效提高客观缓解率、延长无进展生存时间、增加转化切除机会。但对于长期生存获益、选择最优联合方案、筛选合适的目标人群等问题的解决仍需积累临床经验。当前证据表明，HAIC联合索拉非尼对于肝癌合并门静脉主干癌栓疗效确切，联合仑伐替尼或免疫治疗仍需探索，联合免疫及靶向治疗是未来一线治疗的潜在选择。

参考文献/References:

［1］　Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71: 209-249.
［2］　Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66: 115-132.
［3］ Vogel A, Martinelli E, ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma （HCC） from the ESMO clinical practice guidelines［J］. Ann Oncol, 2021, 32: 801-805.
［4］ Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update［J］. Liver Cancer, 2021, 10: 181- 223.
［5］ Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases［J］. Hepatology, 2018, 68: 723-750.
［6］ European Association for the Study of the Liver . EASL clinical practice guidelines: management of hepatocellular carcinoma［J］. J Hepatol, 2018, 69: 182-236.
［7］ Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma Nature reviews［J］. Dis Primers, 2021, 7: 6.
［8］　赵东旭，张　磊，姜小庆，等. HAIC是老技术还是新方法——理性看待肝动脉灌注化疗［J］. 介入放射学杂志，2022，31：2-8.
［9］ Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med, 2008, 359: 378-390.
［10］ Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial［J］. Lancet Oncol, 2009, 10: 25–34.
［11］ Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase Ⅱ trial［J］. Ann Oncol, 2016, 27: 2090-2096.
［12］ Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma （SILIUS）: a randomised, open label, phase 3 trial［J］. Lancet Gastroenterol Hepatol, 2018, 3: 424-432.
［13］ Kondo M, Morimoto M, Kobayashi S, et al. Randomized, phase Ⅱ trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial［J］. BMC Cancer, 2019, 19: 954.
［14］ He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial［J］. JAMA Oncol, 2019, 5: 953-960.
［15］ Wang X, Zheng K, Cao G, et al. 984P Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma with major portal vein tumor thrombosis（Vp3/4）: a randomized phase Ⅱ trial［J］. Ann Oncol, 2020, 31: S689.
［16］ Kudo M, Finn RS, Qin SK, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial［J］. Lancet, 2018, 391: 1163-1173.
［17］ Mai Q, Mo Z, Shi F, et al. Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma［J］. J Clin Oncol, 2020, 38（15_suppl）:e16603.
［18］ Ikeda M, Yamashita T, Ogasawara S, et al. Multicenter phase Ⅱ trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD［J］. Ann Oncol, 2021, 32: S821-S822.
［19］ Rech AJ, Dada H, Kotzin JJ, et al. Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer［J］. Cancer Res, 2018, 78: 4282-4291.
［20］ Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma［J］. J Hepatol, 2017, 66: 545-551.
［21］ Vogel A, Saborowski A, Hinrichs J, et al. IMMUTACE: a biomarker- orientated, multi center phaseⅡAIO study of transarterial chemoembolization（TACE）in combination with nivolumab performed for intermediate stage hepatocellular carcinoma（HCC）［J］. Ann Oncol, 2021, 32: S1312.
［22］ Xu L, Zhang Y, Wang X, et al. Transarterial infusion chemotherapy （TAI） combined with sintilimab in locally advanced, potentially resectable hepatocellular carcinoma （HCC）［J］. J Clin Oncol,2020, 38（15_suppl）:e16593.
［23］ Mei J, Li SH, Li QJ, et al. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma［J］. J Hepatocell Carcinoma, 2021, 8: 167-176.
［24］ Gu YK, Zhang TQ, Huang ZL, et al. Hepatic artery infusion chemotherapy combined with apatinib and toripalimab in advanced hepatocellular carcinoma: real-world data from a single center［J］. J Clin Oncol, 2020, 38（15_suppl）:e16602.
［25］ He MK, Ming S, Lai Z, et al. A phaseⅡtrial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma （LTHAIC study）［J］. J Clin Oncol, 2021, 39（15_suppl）:4083.
［26］ Zhang TQ, Zuo MX, Geng Z J, et al. 946P Hepatic artery infusion chemotherapy （HAIC） combined with apatinib and camrelizumab for hepatocellular carcinoma （HCC） in BCLC stage C: a prospective, single-arm, phaseⅡtrial （TRIPLET study）［J］. Ann Oncol, 2021, 32: S825.
［27］ He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma［J］. Ther Adv Med Oncol, 2021, 13: 17588359211002720.
［28］Mei J, Tang YH, Wei W, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma［J］. Front Oncol, 2021, 11: 618206.
［29］陈敏山，胡自力. 肝动脉灌注化疗在肝癌转化治疗中的研究进展［J］. 中华消化外科杂志，2021，20：171-177．
［30］陈晓明，程永德. 中期肝癌TACE之争论与研究现状［J］. 介入放射学杂志，2021，30：751-755．
［31］ Xue J, Ni H, Wang F, et al. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy［J］. J Interv Med, 2021, 4: 105-113.

相似文献/References:

[1]李晓光,金征宇,潘杰,等.肝动脉化疗或栓塞治疗胰腺神经内分泌肿瘤肝转移的疗效分析[J].介入放射学杂志,2010,(06):442.
　LI Xiaoguang,JIN Zhengyu,PAN Jie,et al.Hepatic transarterial chemoperfusion and chemoembolization for the treatment of liver metastases from pancreatic neuroendocrine tumors：a therapeutic analysis[J].journal interventional radiology,2010,(01):442.
[2]陈伟敏,罗佐权.肝癌肝动脉灌注化疗与静脉输注硫代硫酸钠的“双路”疗法18例报告[J].介入放射学杂志,1992,(01):26.
[3]牛树茂,徐元贞,赵殿有,等.肝动脉灌注化疗后引起带状疱疹样皮疹六例报告[J].介入放射学杂志,1994,(01):54.
[4]秦伟,巫北海.5-FUDR经肝动脉灌注致硬化性胆管炎[J].介入放射学杂志,1996,(01):59.
[5]徐中琪,刘晟,许贇,等.完全性胸腹腔内脏反位合并原发性肝癌行经皮微波消融治疗4例[J].介入放射学杂志,2016,(06):546.
　XU Zhong-qi,LIU Sheng,XU Yun,et al.Percutaneous microwave ablation for primary hepatocellular carcinoma in patients with thoracic and abdominal situs inversus totalis: report of 4 cases [J].journal interventional radiology,2016,(01):546.
[6]中国抗癌协会肿瘤介入学专业委员会,中国抗癌协会肿瘤介入学专业委员会化疗与免疫治疗分委会.改良式经皮肝动脉化疗药盒植入技术中国专家共识（2022版）[J].介入放射学杂志,2022,31(07):633.
　Professional Committee of Oncology Intervention,China Anti-Cancer Association,Chinese expert consensus on the modified implantation technique of port-catheter system for percutaneous hepatic arterial infusion chemotherapy（version 2022）[J].journal interventional radiology,2022,31(01):633.
[7]曹莉明,张勇学,梁志会,等.载药微球栓塞治疗传统TACE抵抗的原发性肝癌临床疗效[J].介入放射学杂志,2023,32(01):59.
　CAO Liming,ZHANG Yongxue,LIANG Zhihui,et al.Drug-eluting beads-trancatheter arterial chemoembolization for the treatment of hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization: observation of its clinical effect[J].journal interventional radiology,2023,32(01):59.
[8]曹佳伟,李慧婷,徐玲玲,等.晚期肝癌患者行HAIC术后股动脉并发假性动脉瘤致骨筋膜室综合征的护理1例[J].介入放射学杂志,2024,33(04):459.
　CAO Jiawei,LI Huiting,XU Lingling,et al.Nursing care for osteofascial compartment syndrome caused by iatrogenic pseudoaneurysm in one patient with advanced liver cancer after receiving hepatic artery infusion chemotherapy[J].journal interventional radiology,2024,33(01):459.
[9]沈晓娣,叶盼,边雪梅,等.基于抑木扶土理论的气交灸联合揿针干预经导管肝动脉化疗栓塞术后疼痛、恶心呕吐的临床研究[J].介入放射学杂志,2024,33(09):1014.
　SHEN Xiaodi,YE Pan,BIAN Xuemei,et al.The“suppressing wood-supporting earth” theory-based air moxibustion combined with pushpin-like needle acupuncture in the treatment of pain，nausea and vomiting after TACE：a clinical study[J].journal interventional radiology,2024,33(01):1014.
[10]张岩基,王汇源,李浩,等.经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展[J].介入放射学杂志,2024,33(09):1039.
　ZHANG Yanji,WANG Huiyuan,LI Hao,et al.Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma[J].journal interventional radiology,2024,33(01):1039.

备注/Memo

备注/Memo:
（收稿日期：2021-12-09）
（本文编辑：新　宇）
更新日期/Last Update: 2023-02-13